UCB S.A. Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Technology Initiatives, ICT, Partnerships, Investments & Acquisitions, Network Map [Yahoo!...
UCB SA UNSP/ADR (UCBJY)
NASDAQ:AMEX Investor Relations:
ucb.com/investors
Company Research
Source: Yahoo! Finance
Their focus on digital transformation, innovation, and tech partnerships aims to advance product launches and strategic initiatives in these therapeutic areas. Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: UCB - 2025" company profile has been added to ResearchAndMarkets.com's offering. The report provides insights into the company's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives. UCB S.A. (UCB) is a multinational company specializing in the development and production of biopharmaceuticals for autoimmune and neurological diseases, including Psoriasis, Hidradenitis suppurativa, Myasthenia Gravis, Epilepsy, Axial Spondyloarthritis, Osteoporosis, Parkinson's disease, CDKL5 Deficiency Disorder, Dravet syndrome, Lennox-Gastaut syndrome, Lupus, Psoriatic Arthritis, Rheumatoid Arthritis, and Thymidine Kinase 2 deficiency, among others. Some of the company's flagship products
Show less
Read more
Impact Snapshot
Event Time:
UCBJY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UCBJY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UCBJY alerts
High impacting UCB SA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
UCBJY
News
- Myasthenia Gravis Foundation of America Launches MGFA Food Support Program to Advance Nutrition Access and Health Equity for Individuals with Myasthenia GravisPR Newswire
- UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science [TheStreet.com]TheStreet.com
- UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative sciencePR Newswire
- UCB (UCBJY) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting [TheStreet.com]TheStreet.com